BVI will showcase Virtuoso, a dual-function surgical platform designed for both cataract and vitreoretinal procedures, at the 2025 EURetina Congress in Paris. The Virtuoso platform will be included in the scientific program, with data about post-occlusion break surge, energy delivery consistency, vitrectomy probe stiffness, and aspiration efficiency.

According to BVI, Virtuoso integrates advanced fluidics control, ultrasound delivery, and aspiration performance into a single platform intended to support both anterior and posterior segment surgeries. Virtuoso has not yet received CE mark approval or US Food and Drug Administration 510(k) clearance; it is currently undergoing a premarket clinical investigation at LMU Klinikum in Munich, Germany. RP